Trials / Completed
CompletedNCT00639678
A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects
A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) in Healthy Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 322 (actual)
- Sponsor
- Human Genome Sciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the safety and tolerability of raxibacumab in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo | 40 mg/kg intravenously, double dose (day 0 and 14), Group 3 |
| DRUG | raxibacumab | 40 mg/kg intravenously, double dose (day 0 and 14), Group 1 |
| DRUG | placebo | 40 mg/kg placebo, single dose (day 0), Group 4 |
| DRUG | raxibacumab | 40 mg/kg intravenously, single dose, day 0, Group 2 |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-07-01
- Completion
- 2008-09-01
- First posted
- 2008-03-20
- Last updated
- 2018-11-15
- Results posted
- 2014-02-07
Source: ClinicalTrials.gov record NCT00639678. Inclusion in this directory is not an endorsement.